Komori
Other Disclosures4884Kringle Pharma,Inc.Pharmaceuticals

Hayata Taishin (早田大真), our director, executive officer and head of the Pharmaceutical Development Department, will speak at "WISH & SEEDs Matching Event 2026"

The company announced that its director and executive officer is scheduled to speak at the industry-academia collaboration event "WISH & SEEDs Matching Event 2026," to be held on 27 November 2026. Through the event, the company aims to introduce its business and research and development activities and promote interaction and collaboration with universities, research institutions and related companies.

Worth reading
51Recurring
Scored from 5 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

oremepermin alfa (オレメペルミン アルファ)
Applicable field (uses covered by this announcement)

Industry-academia collaboration, new research and development, pharmaceutical research and development for rare diseases, the acute phase of spinal cord injury, vocal cord scarring

Launch date27 November 2026 (scheduled; event date)
Relationship between the counterparty and the company
Kringle Pharma,Inc.4884
Relationship with the Company

The event's speakers, participating companies and organiser. No capital, personnel or business relationships are described.

CounterpartyACTjapanMARCLINK-JJapan Biotech Council

ACTjapan is a Japan translational research alliance involving 35 research institutions nationwide, centred on Osaka University. MARC is a metropolitan-area AR consortium comprising clinical research institutions, mainly private universities in the Tokyo metropolitan area, including Keio University. No detailed overview is provided for LINK-J or the Japan Biotech Council.

Location (as indicated in this announcement)

Nihonbashi Life Science Hub

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services Coveredoremepermin alfa (オレメペルミン アルファ)
CounterpartyACTjapan, MARC, LINK-J, Japan Biotech Council
Counterparty overviewACTjapan is a Japan translational research alliance involving 35 research institutions nationwide, centred on Osaka University. MARC is a metropolitan-area AR consortium comprising clinical research institutions, mainly private universities in the Tokyo metropolitan area, including Keio University. No detailed overview is provided for LINK-J or the Japan Biotech Council.
Relationship with the CompanyThe event's speakers, participating companies and organiser. No capital, personnel or business relationships are described.
Launch date27 November 2026 (scheduled; event date)
Applicable areaIndustry-academia collaboration, new research and development, pharmaceutical research and development for rare diseases, the acute phase of spinal cord injury, vocal cord scarring
LocationNihonbashi Life Science Hub
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To introduce the company's business and research and development activities through participation in an event that connects companies' research and development needs with research results and technology seeds from universities and research institutions, thereby creating opportunities for industry-academia collaboration and new research and development, and to foster interaction and collaboration with academia and related companies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Hayata Taishin (早田大真), our director, executive officer and head of the Pharmaceutical Development Department, will speak at "WISH & SEEDs Matching Event 2026" | Kringle Pharma,Inc. (4884) timely disclosure | Komori